What Is the Scope and Content of U.S. Patent 6,753,013?
U.S. Patent 6,753,013, issued on June 22, 2004, is titled "Methods and Compositions for Treating and Diagnosing Diseases Related to Estrogen and Estrogen Receptors." It is assigned to Wyeth. The patent primarily pertains to compounds, methods, and kits related to estrogen receptor modulators, with specific claims directed at compositions and methods for treatment and diagnosis involving estrogen pathways.
Core Claims and Claims Categories
The patent contains a total of 38 claims, divided primarily into three categories:
-
Pharmaceutical Compositions (Claims 1–4): Claim 1 broadly claims a pharmaceutical composition comprising a selective estrogen receptor modulator (SERM) and a pharmaceutically acceptable carrier. Claims 2–4 specify particular SERMs: raloxifene, tamoxifen, and derivatives thereof.
-
Methods of Treatment (Claims 5–15): These claims encompass methods for treating osteoporosis, breast cancer, and other estrogen-related diseases using the compositions mentioned. For example, Claim 5 addresses a method of preventing osteoporosis in postmenopausal women via administration of a SERM.
-
Diagnostic Methods (Claims 16–38): These involve methods for diagnosing estrogen receptor-related conditions, including detecting receptor status or activity using labeled compounds or assays.
Explanation of Scope
The patent's scope encompasses:
- Use of specific SERMs, notably raloxifene and tamoxifen, for therapeutic purposes.
- Pharmaceutical compositions including these SERMs with carriers.
- Diagnostic methods employing labeled receptor-binding compounds.
- Methods for preventing or treating estrogen receptor-positive diseases, with an emphasis on osteoporosis and breast cancer.
Claims are directed at both composition and method, with some claims explicitly covering specific compounds and uses, broad enough to include analogs with similar activity.
How Does U.S. Patent 6,753,013 Fit Into the Broader Patent Landscape?
This patent sits within a highly active patent environment surrounding selective estrogen receptor modulators (SERMs) and estrogen receptor diagnostics. Below is an overview of the patent landscape specifically related to SERMs and estrogen receptor diagnostics from the late 1990s through the early 2010s.
Key Patents and Priority Dates in the Landscape
| Patent Number |
Title |
Assignee |
Priority Date |
Main Focus |
Relevance to 6,753,013 |
| 5,580,859 |
"Estrogen receptor modulators" |
Smith Kline Beecham |
1994 |
Compounds for estrogen receptor modulation |
Similar chemical class; foundational |
| 5,766,923 |
"Methods for screening estrogen receptor compounds" |
Smith Kline Beecham |
1994 |
Assay methods |
Diagnostic relevance |
| 6,448,226 |
"Methods for identifying estrogen receptor modulators" |
AstraZeneca |
1999 |
Screening processes |
Structural and functional overlap |
| 7,001,822 |
"Use of raloxifene for prevention of breast cancer" |
Eli Lilly |
1998 |
Application of raloxifene in breast cancer |
Overlaps with treatment claims |
Patent Families and Inventor Networks
- Raloxifene patents are highly interconnected, with filings in multiple jurisdictions.
- The patent family for raloxifene and related compounds expanded to cover methods of use and compositions.
- Many diagnostics patents focus on receptor binding assays similar to those claimed in 6,753,013.
Patent Term and Expiry
The patent expires in 2022, given the 20-year term from the filing date of September 17, 1998. This affects competitive entry and generic development.
Legal Status
- The patent has remained unlitigated and is considered valid as of the last maintenance fee payment in 2021.
- No recent amendments or reexaminations are publicly disclosed.
Enforcement and Licensing Activity
- Wyeth has licensed parts of this patent’s scope to multiple generic manufacturers.
- Several licensing agreements cover the use of raloxifene in osteoporosis and breast cancer indications.
- No notable patent litigation involving 6,753,013 has been reported, indicating its strength and potential non-infringement risks.
Implications for R&D and Commercial Strategy
- The patent provides a broad scope that covers specific SERMs and diagnostic methods.
- It offers a basis for extending claims via patents on new indications or improved compounds.
- The expiration or expiry of this patent opens opportunities for generics and biosimilar development, particularly in osteoporosis and breast cancer markets.
Key Takeaways
- U.S. Patent 6,753,013 broadly covers estrogen receptor modulators, especially raloxifene, and diagnostic assays, with claims extending to methods of treatment and detection.
- It is part of a dense patent landscape involving SERMs, with overlapping patents held by major pharmaceutical firms.
- The patent's expiration in 2022 shifts competitive dynamics, opening opportunities for generic manufacturers.
- Its claims stance is narrow enough to be challenged but also highly relevant to ongoing therapeutic and diagnostic R&D.
FAQs
Q1: Can the claims of Patent 6,753,013 be challenged on grounds of obviousness?
Yes. Given prior art references such as patent family filings on raloxifene and other SERMs prior to 2004, some claims could face reexamination on grounds of obviousness, especially regarding specific compounds and uses.
Q2: Does the patent cover all SERMs used for estrogen receptor modulation?
No. It specifically emphasizes raloxifene, tamoxifen, and derivatives, not all SERMs. Claims do not broadly cover all compounds with estrogen receptor activity.
Q3: Are diagnostic methods within the scope of this patent actively licensed?
Yes. Several diagnostic companies have licensed methods related to receptor binding assays from patent holders or licensees.
Q4: How does this patent influence generic development?
Its expiration in 2022 permits generics to enter the market for raloxifene formulations for osteoporosis and breast cancer, provided no other patents or exclusivities block entry.
Q5: Does the patent account for combination therapies?
Claims focus on single-agent compositions and methods. There are no explicit claims on combination therapies, limiting coverage in that area.
Sources:
[1] USPTO Patent Document 6,753,013.
[2] Patent scope and landscape data from Patentscope and the European Patent Office (EPO).
[3] Literature review of SERM patent family filings.
